1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022

Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022

  • April 2014
  • -
  • GlobalData
  • -
  • 88 pages

Summary

Table of Contents

Topical Clonidine (Neuropathic Pain) - Forecast and Market Analysis to 2022

Summary

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.

BioDelivery Sciences International (BDSI) is currently planning Phase III clinical trials of a Topical Clonidine gel (0.1% clonidine hydrochloride) for the treatment of PDN, after the company entered into a worldwide licensing agreement with Arcion Therapeutics for clonidine in March 2013. Arcion had previously completed Phase II trials of the drug in PDN in December 2009, the results of which showed that it was effective in reducing pain associated with PDN, particularly in subjects with evidence of preserved nociceptors. In September 2010, Arcion Therapeutics received a Fast-Track designation from the FDA for the topical clonidine gel for the treatment of pain associated with PDN.

Scope

- Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Topical Clonidine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Topical Clonidine for the top six countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic pain
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Topical Clonidine performance
- Obtain sales forecast for Topical Clonidine from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • January 2017
  • by GlobalData

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the Netherlands and Germany

  • April 2017
    10 pages
  • Anti-Infective  

  • Netherlands  

    Germany  

    Europe  

View report >

Cardiovascular Disease Statistics in the US and the UK

  • April 2017
    8 pages
  • Cardiovascular ...  

    Therapy  

  • United States  

View report >

Opioid Market and Digestive System Disorder Statistics in the US

  • April 2017
    20 pages
  • Opioid  

    Digestive Syste...  

  • United States  

View report >

Cranberry Industry

15 days ago

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.